Hubei Goto Biopharm Co.,Ltd. (SHE:300966)

Hubei Goto Biopharm Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	157.14	141.18	181.97	438.42	209.91	28.96
Trading Asset Securities	0	0	0	15.01	0.1	-
Cash & Short-Term Investments	157.14	141.18	181.97	453.43	210.02	28.96
Cash Growth	34.55%	-22.42%	-59.87%	115.90%	625.10%	-77.66%
Accounts Receivable	240.79	214.26	235.4	269.36	243.86	312.53
Other Receivables	3.67	2.05	2.15	1.88	2.09	0.72
Receivables	244.46	216.31	237.54	271.25	245.95	313.26
Inventory	433.17	384.8	396.16	432.5	371.24	200.74
Prepaid Expenses	-	-	-	-	1.68	1.27
Other Current Assets	37.65	27.7	54.06	56.56	29.37	35.42
Total Current Assets	872.43	770	869.73	1,214	858.26	579.64
Property, Plant & Equipment	1,861	1,849	1,391	610.94	256.57	198.11
Long-Term Investments	48.32	48.27	48.24	48.08	14.47	-
Other Intangible Assets	49.6	49.88	51	43.14	27.82	21.06
Long-Term Deferred Tax Assets	40.91	37.29	22.62	17.89	8.82	3.43
Long-Term Deferred Charges	8.8	9.69	13.3	13.96	0.97	1.93
Other Long-Term Assets	32.18	25.78	51.96	121.56	44.34	0.26
Total Assets	2,914	2,790	2,448	2,069	1,211	804.43
Accounts Payable	465.69	459.91	532.24	205.52	138.17	74.12
Accrued Expenses	6.37	12.43	9.25	9.58	7.51	6.4
Short-Term Debt	291.24	294.3	110.09	321.63	143.41	118
Current Portion of Long-Term Debt	28.45	24.55	22.27	5.24	-	-
Current Portion of Leases	-	0.06	0.45	1.98	11.47	21.77
Current Income Taxes Payable	0.4	0.08	2.8	7.21	11.27	5.73
Current Unearned Revenue	2.1	1.23	3.47	2.01	3.7	0.19
Other Current Liabilities	33.07	15.13	5.84	22.79	17.65	20.92
Total Current Liabilities	827.33	807.69	686.41	575.97	333.18	247.13
Long-Term Debt	920.14	812.64	652.37	437.04	-	-
Long-Term Leases	-	-	0.54	4.41	6.67	9.75
Long-Term Unearned Revenue	149.36	150.25	84.33	69.71	42.98	7.69
Long-Term Deferred Tax Liabilities	0.01	0.01	0.29	0.97	0	-
Other Long-Term Liabilities	4.65	4.65	0.03	0.05	-	0.02
Total Liabilities	1,901	1,775	1,424	1,088	382.83	264.58
Common Stock	115.28	115.28	115.28	115.28	115.28	86.28
Additional Paid-In Capital	410.71	410.6	410.77	409.11	409.11	243.92
Retained Earnings	301.85	300.77	330.2	307.2	282.67	204.34
Comprehensive Income & Other	96.49	96.49	96.49	96.51	-	-
Total Common Equity	922.4	923.14	952.75	928.09	807.05	534.54
Minority Interest	89.66	91.5	71.03	53.07	21.36	5.31
Shareholders' Equity	1,012	1,015	1,024	981.16	828.42	539.85
Total Liabilities & Equity	2,914	2,790	2,448	2,069	1,211	804.43
Total Debt	1,240	1,132	785.73	770.3	161.54	149.51
Net Cash (Debt)	-1,083	-990.37	-603.75	-316.87	48.47	-120.55
Net Cash Per Share	-9.63	-8.61	-5.25	-2.76	0.46	-1.40
Filing Date Shares Outstanding	115.28	115.28	115.28	115.28	115.28	115.28
Total Common Shares Outstanding	115.28	115.28	115.28	115.28	115.28	86.28
Working Capital	45.1	-37.69	183.33	637.76	525.08	332.52
Book Value Per Share	8.00	8.01	8.26	8.05	7.00	6.20
Tangible Book Value	872.8	873.26	901.75	884.95	779.23	513.48
Tangible Book Value Per Share	7.57	7.58	7.82	7.68	6.76	5.95
Buildings	-	506.33	129.73	108.67	95.53	91.93
Machinery	-	820.79	207.89	196.16	180.78	175.11
Construction In Progress	-	694.41	1,182	411.99	66.38	5.3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.